Organization
Pfizer Inc, Inflammation and Immunology, New York, NY, United States of America
3 abstracts
Abstract
ASSOCIATION BETWEEN BASELINE CARDIOVASCULAR RISK AND INCIDENCE RATES OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MALIGNANCIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS RECEIVING TOFACITINIBOrg: Central Connecticut Dermatology Research, Cromwell, CT, United States of America, Charité Universitätsmedizin, Department of Rheumatology, Infectious Diseases and Rheumatology, Berlin, Germany, German Rheumatism Research Center Berlin, Epidemiology, Berlin, Germany, Pfizer Inc, Inflammation and Immunology, Groton, CT, United States of America, Pfizer Inc, Inflammation and Immunology, New York, NY, United States of America,
Abstract
ANALYSIS OF THE IMPACT OF TOFACITINIB TREATMENT ON WEIGHT IN PATIENTS WITH RHEUMATOID ARTHRITISOrg: Struenseehaus Centre for Rheumatology and Clinical Immunology, Hamburg, Germany, CHU Montpellier and University of Montpellier, Department of Rheumatology, Montpellier, France, Hopital Purpan, CHU Toulouse, Department of Rheumatology, Toulouse, France, Groupe Hospitalier Pellegrin-CHU de Bordeaux, Department of Rheumatology, Bordeaux, France, Pfizer Inc, Inflammation and Immunology, Peapack, NJ, United States of America,
Abstract
Back pain and morning stiffness as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysisOrg: Copenhagen University Hospital, Bispebjerg and Frederiksberg, The Parker Institute, Copenhagen, Denmark, University of Oxford, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, University Hospital La Paz, IdiPaz, Madrid, Spain, Case Western Reserve University, Division of Rheumatology, Cleveland, OH, United States of America, Pfizer Inc, Inflammation and Immunology, Groton, CT, United States of America,